SS-31

What is SS-31?

SS-31, widely known as elamipretide, is a synthetic, cell-permeable peptide that belongs to the Szeto-Schiller family of mitochondria-targeted compounds. In September 2025, it became the first mitochondria-targeted therapeutic ever to receive FDA accelerated approval under the brand name FORZINITY, specifically to improve muscle strength in patients with Barth syndrome.

Barth syndrome is a rare, life-threatening genetic disorder of mitochondrial cardiolipin metabolism. While the approval marks a milestone for rare metabolic diseases, it is crucial to note that SS-31 has generated significant hype as an anti-aging or chronic fatigue treatment. Despite its plausible cellular mechanism, clinical trials for broader, common conditions-such as primary mitochondrial myopathy, chronic heart failure, and age-related decline-have consistently failed to meet their primary endpoints. Therefore, there is currently no clinical evidence supporting its use for everyday exhaustion, athletic recovery, or general anti-aging purposes.

How does SS-31 work?

In simple terms, SS-31 works like a tiny patch for the inner wall of the cell's power plants: inside each cell's mitochondria sits a special fat-like molecule called cardiolipin, which keeps the membrane folded into shape so the cell can produce ATP - the universal 'fuel' molecules cells run on. SS-31 docks specifically onto cardiolipin and stabilizes the membrane, which restores ATP production.

SS-31 works by selectively binding to cardiolipin, a phospholipid exclusively located in the inner mitochondrial membrane. This highly specific interaction repairs membrane geometry, stabilizes the mitochondrial cristae, lowers the output of reactive oxygen species, and restores cellular ATP synthesis without altering normal physiological functions.

Unlike other metabolic peptides like MOTS-c, which primarily influence mitochondrial gene expression and glucose metabolism, elamipretide operates purely structurally. By interacting with the hydrophobic acyl chains and the phosphate headgroups of cardiolipin, SS-31 maintains the structural integrity of the inner membrane. This structural stabilization is crucial because damaged cardiolipin leads to impaired electron transport, increased oxidative stress, and cellular energy failure. Preclinical models show that repairing this membrane geometry enhances mitophagy (the clearance of damaged mitochondria) and improves overall cellular resilience, though this biological plausibility has rarely translated into broad clinical success.

How effective is SS-31?

The clinical efficacy of SS-31 is highly specific and limited to Barth syndrome. While the FDA granted accelerated approval based on a tiny Phase 2/3 trial showing improved knee extensor strength, comprehensive phase 3 trials for primary mitochondrial myopathies and chronic heart failure failed to demonstrate any statistically significant benefits.

The FDA approval rested entirely on the TAZPOWER trial. This Phase 2/3 crossover study involved only 12 patients receiving 40 mg of subcutaneous elamipretide over 12 weeks, followed by a 168-week open-label extension. While the trial initially missed its co-primary endpoints (6-minute walk test and fatigue score), the long-term extension showed clinically meaningful improvements in knee extensor strength and in the 6-minute walk distance compared to baseline.

Conversely, the drug completely failed in broader indications. The MMPOWER-2 trial in primary mitochondrial myopathy missed its primary endpoints (muscle endurance and walking distance) after 24 weeks, showing no significant advantage over placebo. Similarly, large-scale studies investigating its use for chronic heart failure yielded negative results. Following these failures, the manufacturer halted development plans for the broader indications and subsequently refocused its efforts, filing a focused NDA for Barth syndrome that received FDA accelerated approval in September 2025. This creates a stark paradox: a structurally profound mechanism that treats ultra-rare monogenic defects, but cannot treat complex, systemic fatigue or heart conditions.

Dosage: what the studies show - and the course

The FDA-approved, study-validated dosage for Barth syndrome is 40 mg administered as a subcutaneous injection once daily for patients weighing at least 30 kg. This regimen utilizes a ready-to-use solution rather than requiring any powder reconstitution, ensuring accurate dosing for the ultra-rare condition.

Prior to the approval of FORZINITY, elamipretide circulated as a research chemical. Research-chemical regimens widely discussed in non-medical forums often suggested conservative orientation doses between 500 and 1,000 mcg (0.5 to 1.0 mg) daily. These unapproved doses were based on early preclinical extrapolation and lack clinical validation for general use. They do not reflect the highly concentrated, pharmaceutical-grade 40 mg therapeutic dose required to achieve clinical efficacy in humans.

Handling & Storage

Handling and storage requirements differ fundamentally between the FDA-approved FORZINITY formulation and unregulated research chemicals. The approved ready-to-use solution must be stored according to specific manufacturer guidelines, typically requiring refrigeration to maintain sterility and peptide stability, whereas research powders require manual reconstitution using bacteriostatic water before subcutaneous administration.

If handling unapproved, lyophilized research powders, harm reduction requires strict aseptic technique. Reconstitution typically involves injecting bacteriostatic water into the vial, allowing the powder to dissolve naturally without aggressive shaking, which can degrade the fragile peptide chains. Once reconstituted, the liquid peptide solution is highly sensitive to temperature and light, requiring constant refrigeration to slow degradation. However, self-reconstituted vials carry inherent risks of contamination and inaccurate dosing, as they are not produced under pharmaceutical Good Manufacturing Practice (GMP) standards.

Side effects and common mistakes

In clinical trials, elamipretide was generally well-tolerated without newly discovered systemic safety signals, though localized reactions at the injection site are frequently reported. Common mistakes include assuming this rare-disease drug acts as a general anti-aging cure or attempting to self-administer unregulated research chemicals without proper medical supervision or sterile technique.

The most frequently reported adverse events across trials were directly related to the subcutaneous delivery method. Patients commonly experience injection site pain, local erythema, itching, and bruising (hematomas). Systemic side effects remained rare and comparable to placebo groups in broader trials. Because the approved formulation is highly concentrated at 40 mg, sterile administration technique is critical to minimize tissue irritation and prevent secondary infections.

• Misinterpreting the approval: Believing FORZINITY is approved for general fatigue, anti-aging, or common heart failure, whereas it is exclusively validated for Barth syndrome.
• Using research chemicals: Purchasing unregulated SS-31 vials and assuming they match the pharmaceutical quality, safety, or concentration of the FDA-approved drug.
• Improper injection hygiene: Failing to rotate injection sites or skipping antiseptic preparation, which drastically increases the risk of painful injection site reactions and bacterial infections.

Regulatory approval and legal status

As of September 2025, SS-31 holds a legal FDA accelerated approval in the USA exclusively under the brand name FORZINITY for Barth syndrome in patients weighing at least 30 kg. It is not approved by the European Medicines Agency (EMA) for any indication, nor is it legally available as a medication in the EU or Germany.

The FDA granted this approval based on the intermediate clinical endpoint of improved knee extensor strength, allowing the drug to reach the market despite the extremely small trial size of 12 individuals. To maintain this accelerated approval in the USA, the manufacturer is legally required to conduct ongoing Phase 3b/4 confirmatory trials to verify its clinical benefit. In the European Union and Germany, elamipretide is not recognized as an approved medicinal product; obtaining it online falls under unregulated research chemical importation, carrying significant legal and health risks.